Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Frequently asked questions
What sector does Trevi Therapeutics Inc (TRVI) operate in?
Trevi Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Trevi Therapeutics Inc (TRVI) current stock price?
As of the latest data, Trevi Therapeutics Inc stock price is $18.08, with a previous close of $17.96. Trevi Therapeutics Inc gained $0.12 in the last trading session, representing a 0.67% increase.
What is Trevi Therapeutics Inc (TRVI) current market capitalization?
Trevi Therapeutics Inc market cap is approximately 2.58 billion.
What is Trevi Therapeutics Inc (TRVI) Earnings Per Share (EPS)?
The trailing EPS is -$0.35, and the forward EPS is -$0.56.
What is Trevi Therapeutics Inc (TRVI) EBITDA?
Trevi Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -17.82 million.
Does Trevi Therapeutics Inc (TRVI) pay dividends?
No. Trevi Therapeutics Inc does not pay a dividend.
What is Trevi Therapeutics Inc (TRVI) beta (volatility) score?
Trevi Therapeutics Inc has a beta of 1.072, meaning its volatility is roughly in line with the market.
